Manufacturer of Controlled Substances; Notice of Application, 30621 [E9-15235]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 122 / Friday, June 26, 2009 / Notices
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 22, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–15228 Filed 6–25–09; 8:45 am]
BILLING CODE 4410–09–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 USC 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title
21, Code of Federal Regulations
1301.34(a), this is notice that on May 22,
2009, Noramco, Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Tapentadol (9780), a basic class of
controlled substance listed in schedule
II.
The company plans to import an
intermediate of the basic class listed for
the bulk manufacture of Tapentadol
which it will distribute to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
VerDate Nov<24>2008
16:39 Jun 25, 2009
Jkt 217001
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than July 27, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 22, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–15233 Filed 6–25–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 19, 2009,
Wildlife Laboratories Inc., 1401 Duff
Drive, Suite 400, Fort Collins, Colorado
80524, made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Carfentanil (9743), a basic class of
controlled substance listed in schedule
II.
The company will manufacture the
above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
PO 00000
Frm 00122
Fmt 4703
Sfmt 4703
30621
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 25, 2009.
Dated: June 22, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–15235 Filed 6–25–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice of a Change in Status of an
Extended Benefit (EB) Period for
Colorado
AGENCY: Employment and Training
Administration, Labor.
ACTION: Notice.
SUMMARY: This notice announces a
change in benefit period eligibility
under the EB program for Colorado.
The following change has occurred
since the publication of the last notice
regarding Colorado’s EB status:
• Colorado has modified its law by
adding a total unemployment rate (TUR)
trigger retroactive to March 22, 2009. As
a result, Colorado has retroactively
triggered ‘‘on’’ to an extended benefit
period for weeks of unemployment
beginning April 12, 2009, and eligible
unemployed workers will be able to
collect up to an additional 13 weeks of
unemployment insurance benefits.
Information for Claimants
The duration of benefits payable in
the EB program, and the terms and
conditions on which they are payable,
are governed by the Federal-State
Extended Unemployment Compensation
Act of 1970, as amended, and the
operating instructions issued to the
states by the U.S. Department of Labor.
In the case of a state beginning an EB
period, the State Workforce Agency will
furnish a written notice of potential
entitlement to each individual who has
exhausted all rights to regular benefits
and is potentially eligible for EB (20
CFR 615.13(c)(1)). Persons who believe
they may be entitled to EB or who wish
to inquire about their rights under the
program should contact their State
Workforce Agency.
FOR FURTHER INFORMATION CONTACT:
Scott Gibbons, U.S. Department of
Labor, Employment and Training
Administration, Office of Workforce
Security, 200 Constitution Avenue,
NW., Frances Perkins Building, Room
S–4231, Washington, DC 20210,
E:\FR\FM\26JNN1.SGM
26JNN1
]]>Agencies
[Federal Register Volume 74, Number 122 (Friday, June 26, 2009)]
[Notices]
[Page 30621]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-15235]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 19, 2009, Wildlife
Laboratories Inc., 1401 Duff Drive, Suite 400, Fort Collins, Colorado
80524, made application to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Carfentanil (9743), a basic
class of controlled substance listed in schedule II.
The company will manufacture the above listed controlled substance
for sale to veterinary pharmacies, zoos, and for other animal and
wildlife applications.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 25, 2009.
Dated: June 22, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-15235 Filed 6-25-09; 8:45 am]
BILLING CODE 4410-09-P
